Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 5;7(12):245.
doi: 10.3390/cells7120245.

Exploring MicroRNA Biomarkers for Parkinson's Disease from mRNA Expression Profiles

Y-H Taguchi  1 , Hsiuying Wang  2
Affiliations

Exploring MicroRNA Biomarkers for Parkinson's Disease from mRNA Expression Profiles

Y-H Taguchi et al. Cells. .

Abstract

Parkinson's disease (PD) is a chronic, progressive neurodegenerative disease characterized by both motor and nonmotor features. The diagnose of PD is based on a review of patients' signs and symptoms, and neurological and physical examinations. So far, no tests have been devised that can conclusively diagnose PD. In this study, we explore both microRNA and gene biomarkers for PD. Microarray gene expression profiles for PD patients and healthy control are analyzed using a principal component analysis (PCA)-based unsupervised feature extraction (FE). 244 genes are selected to be potential gene biomarkers for PD. In addition, we implement these genes into Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, and find that the 15 microRNAs (miRNAs), hsa-miR-92a-3p, 16-5p, 615-3p, 877-3p, 100-5p, 320a, 877-5p, 23a-3p, 484, 23b-3p, 15a-5p, 324-3p, 19b-3p, 7b-5p and 505-3p, significantly target these 244 genes. These miRNAs are shown to be significantly related to PD. This reveals that both selected genes and miRNAs are potential biomarkers for PD.

Keywords: biomarker; gene; microRNA; parkinson’s disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. DeMaagd G., Philip A. Parkinson’s disease and its management: Part 1: Disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. Pharm. Ther. 2015;40:504. - PMC - PubMed
    1. Drui G., Carnicella S., Carcenac C., Favier M., Bertrand A., Boulet S., Savasta M. Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson’s disease. Mol. Psychiatry. 2014;19:358–367. doi: 10.1038/mp.2013.3. - DOI - PMC - PubMed
    1. Neikrug A.B., Maglione J.E., Liu L., Natarajan L., Avanzino J.A., Corey-Bloom J., Palmer B.W., Loredo J.S., Ancoli-Israel S. Effects of sleep disorders on the non-motor symptoms of Parkinson disease. J. Clin. Sleep Med. 2013;9:1119–1129. doi: 10.5664/jcsm.3148. - DOI - PMC - PubMed
    1. Marsh L. Depression and Parkinson’s disease: Current knowledge. Curr. Neurol. Neurosci. Rep. 2013;13:409. doi: 10.1007/s11910-013-0409-5. - DOI - PMC - PubMed
    1. Watson G.S., Leverenz J.B. Profile of cognitive impairment in Parkinson’s disease. Brain Pathol. 2010;20:640–645. doi: 10.1111/j.1750-3639.2010.00373.x. - DOI - PMC - PubMed

LinkOut - more resources